Search

Oxaliplatin

[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. … Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin.

Guanosine

Guanosine is a nucleoside comprising guanine attached to a ribose (ribofuranose) ring via a β-N9-glycosidic bond.

Calcium carbonate

Calcium carbonate is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. … An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. Calcium carbonate may also be used as a nutritional supplement or to treat hypocalcemia.

Amiodarone

Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. … [A36817] Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation.

Gliclazide

a sulfonamide group able to release a proton and the presence of one aromatic group. … [A39546] On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life.

Furosemide

Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. … [A182495] The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential.

Vardenafil

[A258313] The use of vardenafil as a monotherapy for the treatment of pulmonary arterial hypertension has also been evaluated.[A258308] … Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.

Montelukast

a generic and as a brand name product. … Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair.

Clobenzorex

Rolapitant

By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration